Summary
This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international
study to assess the efficacy and safety of durvalumab administered concurrently with dCRT in
patients with locally advanced, unresectable esophageal squamous cell carcinoma (ESCC).